Follicular lymphoma is a type of blood cancer that often returns after treatment, requiring patients to navigate multiple rounds of therapy over many years. When the disease becomes refractory or relapsed, choosing the right treatment approach becomes increasingly complex, balancing disease control with quality of life.

Understanding Treatment Goals When Lymphoma Returns or Resists

Follicular lymphoma is recognized as a chronic illness with a pattern of remitting and relapsing over time. Treatment for relapsed or refractory disease focuses on several important goals. The primary aim is to control disease progression and reduce the burden of cancer in the body. Managing symptoms such as swollen lymph nodes, fatigue, night sweats, and weight loss helps patients maintain their daily activities and overall well-being.^[1]

Another key goal is extending the time between treatments, known as progression-free survival—the period during which the disease does not worsen. Because follicular lymphoma is generally considered incurable, treatment strategies are designed to manage it as a chronic condition rather than to eliminate it completely. This means patients may receive intermittent therapy over decades, with treatment adjusted based on symptoms, disease burden, and how well previous therapies worked.^[1][2]

The treatment landscape for relapsed and refractory follicular lymphoma has evolved significantly. While standard treatments approved by medical societies remain important, researchers are actively testing new therapies in clinical trials. These investigational treatments include targeted drugs, immunotherapies, and cell therapies that work differently from traditional chemotherapy. The choice of treatment depends heavily on factors such as the stage of disease, the patient’s age and overall health, the presence of other medical conditions, and how quickly the disease progressed after the last treatment.^[1][12]

An important factor in treatment decisions is the timing of disease relapse. Patients who experience disease progression within 24 months of starting chemotherapy or within 12 months of receiving rituximab tend to have a poorer outlook. These patients have about a 50% five-year survival rate, which is significantly lower than those who relapse later. This group may benefit from more aggressive treatment approaches or enrollment in clinical trials testing novel therapies.^[1][12]

Standard Treatment Approaches for Relapsed and Refractory Disease

When treatment becomes necessary for relapsed or refractory follicular lymphoma, several established options are available. The foundation of standard treatment typically involves anti-CD20 monoclonal antibodies, particularly rituximab. This type of drug is designed to recognize and attach to a protein called CD20 found on the surface of the cancer cells. Once attached, rituximab marks these cells for destruction by the body’s immune system.^[1][18]

Rituximab can be given alone or combined with chemotherapy drugs. Common chemotherapy combinations include bendamustine with rituximab, which has shown effectiveness in patients who have relapsed. Another option is R-CVP, which combines rituximab with cyclophosphamide, vincristine, and prednisone. The R-CHOP regimen adds doxorubicin to this mix and is sometimes used for more aggressive cases.^[18]

Another monoclonal antibody option is obinutuzumab, also known as Gazyva. Like rituximab, it targets CD20 but works in a slightly different way. It can be combined with chemotherapy drugs such as bendamustine. The choice between rituximab and obinutuzumab may depend on the patient’s previous treatments and how well they responded.^[18]

For patients with localized disease—meaning the lymphoma is limited to one area or a few nearby lymph nodes—radiation therapy may be an effective treatment. Radiation uses high-energy beams to destroy cancer cells in the targeted area. This approach can sometimes produce long-lasting remissions, particularly in early-stage relapsed disease.^[7][17]

Targeted therapy drugs represent another important category of standard treatment. These medications are designed to interfere with specific molecules or pathways that cancer cells need to grow and survive. For example, idelalisib (Zydelig) and copanlisib (Aliqopa) are drugs that block certain enzymes called PI3 kinases, which help cancer cells multiply. These drugs are taken orally or given through an IV and can be effective when the lymphoma has stopped responding to other treatments.^[18]

Umbralisib is another targeted therapy that works similarly by blocking PI3 kinase. Additionally, tazemetostat (Tazverik) represents a different class of targeted drug. It inhibits an enzyme called EZH2, which is involved in controlling which genes are turned on or off in cells. By blocking this enzyme, tazemetostat can slow cancer growth in certain patients whose tumors have specific genetic changes.^[18]

The combination of rituximab with lenalidomide (Revlimid), often called R², offers yet another treatment option. Lenalidomide is an immunomodulatory drug that helps the immune system fight cancer and may also directly affect cancer cells. This combination has shown promise in clinical trials for relapsed follicular lymphoma.^[18]

The duration of treatment varies widely depending on the regimen chosen. Some treatments involve a fixed number of cycles over several months, while others may continue until the disease progresses or side effects become unacceptable. For instance, chemotherapy combinations are typically given in cycles every few weeks for four to six months. Targeted therapies may be taken continuously as long as they remain effective and tolerable.^[1]

All treatments carry potential side effects. Chemotherapy commonly causes fatigue, nausea, hair loss, and increased risk of infections due to lowered white blood cell counts. Rituximab and obinutuzumab can cause infusion reactions during or shortly after administration, including fever, chills, and breathing difficulties. Targeted therapies may cause diarrhea, liver function changes, lung inflammation, and increased blood sugar levels. Radiation therapy can lead to skin changes in the treated area and fatigue. Doctors carefully monitor patients during treatment and can adjust doses or provide supportive care to manage these side effects.^[1][18]

Innovative Treatments Being Tested in Clinical Trials

Research into new treatments for relapsed and refractory follicular lymphoma is very active, with numerous promising therapies being evaluated in clinical trials. These investigational treatments represent different approaches to attacking cancer cells and may offer hope for patients whose disease has not responded to standard therapies.

CAR T-cell therapy is one of the most exciting advances in lymphoma treatment. This approach involves collecting a patient’s own immune cells called T cells, genetically modifying them in a laboratory to recognize and attack lymphoma cells, then infusing them back into the patient. The modified T cells are equipped with a special receptor that targets the CD19 protein found on B cells, including lymphoma cells. Three CAR T-cell therapies have been tested or approved for follicular lymphoma: axicabtagene ciloleucel (Yescarta), tisagenlecleucel (Kymriah), and lisocabtagene maraleucel (Breyanzi).^[18]

These therapies undergo testing in Phase I, Phase II, and Phase III clinical trials. Phase I trials primarily assess safety and determine the appropriate dose. Phase II trials evaluate how well the treatment works in controlling the disease. Phase III trials compare the new treatment to existing standard treatments. CAR T-cell therapies have shown impressive results in clinical trials, with many patients achieving complete remissions even when other treatments have failed. However, they can cause serious side effects, including cytokine release syndrome—a condition where the activated immune cells release large amounts of inflammatory molecules—and neurological complications.^[1][18]

Another promising area involves drugs that target the EZH2 enzyme. Tazemetostat has already been approved, but researchers continue to study it in combination with other drugs. EZH2 is part of a system that controls gene activity by modifying how DNA is packaged. When EZH2 is overactive or mutated, it can promote cancer growth. By inhibiting this enzyme, tazemetostat can restore normal gene regulation and slow tumor growth. Clinical trials have shown that tazemetostat can produce responses in patients with heavily pretreated follicular lymphoma, particularly those whose tumors carry EZH2 mutations.^[1][18]

Bispecific antibodies represent another innovative class of drugs being tested in trials. These specially designed antibodies can simultaneously bind to two different targets—typically one protein on the cancer cell and another on an immune cell. By bringing these cells together, bispecific antibodies help the immune system recognize and destroy cancer cells. Several bispecific antibodies targeting CD20 on lymphoma cells and CD3 on T cells are in various stages of testing. Early results from clinical trials have been encouraging, showing responses in patients whose disease progressed after multiple prior treatments.^[12]

PI3 kinase inhibitors beyond those already approved are also being studied. Copanlisib has shown activity in relapsed follicular lymphoma by blocking the PI3K pathway, which is important for cancer cell survival and growth. It is given intravenously rather than orally, which may offer advantages for some patients. Clinical trials have demonstrated that copanlisib can shrink tumors and provide disease control in patients who have received multiple prior therapies.^[12][18]

Some clinical trials are exploring combinations of these new drugs with existing treatments. For example, researchers are testing whether adding targeted therapies to immunotherapy can improve outcomes. Others are studying whether giving these drugs in earlier lines of treatment, rather than waiting until multiple prior therapies have failed, might be more effective.^[12]

The location of clinical trials varies, with studies being conducted at major cancer centers throughout the United States, Europe, and other regions. Some trials are specific to certain institutions, while others involve multiple centers collaborating together. To be eligible for a trial, patients typically need to meet specific criteria regarding their disease characteristics, prior treatments, and overall health status. These requirements are designed to ensure patient safety and help researchers answer specific scientific questions.^[1]

Hematopoietic stem cell transplantation, also called bone marrow transplant, remains an option for select patients with relapsed or refractory follicular lymphoma, particularly those who are younger and have good overall health. This intensive procedure involves using high doses of chemotherapy or radiation to destroy cancer cells, followed by infusion of healthy stem cells to rebuild the blood and immune system. The stem cells may come from the patient (autologous transplant) or from a donor (allogeneic transplant). While transplantation can produce long-lasting remissions, it carries significant risks including infections, graft-versus-host disease (in donor transplants), and organ damage.^[1]

Most common treatment methods

• Monoclonal antibody therapy
  • Rituximab (Rituxan) targets the CD20 protein on cancer cells, marking them for immune system destruction
  • Obinutuzumab (Gazyva) also targets CD20 but with a different mechanism of action
  • Can be used alone or combined with chemotherapy
  • May cause infusion reactions, fever, chills, and increased infection risk
• Chemotherapy combinations
  • Bendamustine with rituximab or obinutuzumab for relapsed disease
  • R-CVP (rituximab, cyclophosphamide, vincristine, prednisone)
  • R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone)
  • Fludarabine-based regimens for certain patients
  • Common side effects include fatigue, nausea, hair loss, and low blood counts
• Targeted therapy
  • PI3 kinase inhibitors (idelalisib, copanlisib, umbralisib) block enzymes needed for cancer cell growth
  • Tazemetostat inhibits the EZH2 enzyme involved in gene regulation
  • Lenalidomide combined with rituximab helps immune system fight cancer
  • Side effects vary by drug but may include diarrhea, liver changes, lung inflammation
• CAR T-cell therapy
  • Axicabtagene ciloleucel (Yescarta), tisagenlecleucel (Kymriah), and lisocabtagene maraleucel (Breyanzi)
  • Patient’s T cells are modified to recognize and attack CD19-positive cancer cells
  • Can produce complete remissions in heavily pretreated patients
  • Potential serious side effects include cytokine release syndrome and neurological problems
• Radiation therapy
  • Uses high-energy beams to destroy cancer cells in localized areas
  • Particularly effective for early-stage or localized relapsed disease
  • Can sometimes produce long-lasting remissions
  • Side effects include skin changes and fatigue in treated areas
• Stem cell transplantation
  • Autologous transplant uses patient’s own stem cells
  • Allogeneic transplant uses donor stem cells
  • Reserved for select patients with good overall health
  • Can produce long-term disease control but carries significant risks